Introduction

Name

• Grapiprant.

Class of drug

• Prostaglandin E2 EP4 receptor antagonist (piprant).
• Non-cycloxygenase inhibiting, non-steroidal anti-inflammatory drug.

Description

Chemical name

• N-[[[2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4 methylbenzenesulfonamide.

Molecular formula

• C26H29N5O3S

Molecular weight

• 491.61

Physical properties

• Beige to brown, flavored tablet.

Storage requirements

• Store at or below 86° F (30° C).

Uses

Indications

• Indicated for the control of pain and inflammation associated with osteoarthritis Arthritis: osteoarthritis in dogs.

Administration

Precautions

Interactions

With other drugs

• Concurrent use with other anti-inflammatories has not been studied.
• Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided.
• Use with caution with other highly plasma protein bound drugs.

With diagnostic tests

• Some dogs may develop decreased serum albumin and total protein.

Adverse Reactions

Further Reading

Publications

Refereed papers

• Recent references from PubMed and VetMedResource.
• Nagahisa A & Okumura T (2017) Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. J Vet Thermacol 40 (3), 285-292 PubMed.
• Kirkby Shaw K, Rausch-Derra L C & Rhodes L (2016) Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci 2 (1), 3-9 PubMed.
• Rausch-Derra L, Rhodes L, Freshwater L et al (2016) Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. J Vet Pharmcol Ther 39 (6), 566-571 PubMed.
• Rausch-Derra L, Huebner M, Wofford J et al (2016) A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J Vet Int Med 30 (3), 756-763 PubMed.
• Rausch-Derra L, Huebner M & Rhodes L (2015) Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritis pain and inflammation, in healthy dogs. Am J Vet Res 76 (10), 853-859 PubMed.

Other sources of information

• Elanco: www.galliprantvet.com/us/en/product
• www.galliprantfordogs.com/
• www.galliprant.co.uk
• US Food and Drug Administration: animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/941.